

# Merlin C Thomas

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3582268/merlin-c-thomas-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

175 papers	9,183 citations	49 h-index	93 g-index
180 ext. papers	10,534 ext. citations	6.5 avg, IF	6.18 L-index

#	Paper	IF	Citations
175	The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. <i>Diabetes</i> , <b>2009</b> , 58, 1651-8	0.9	410
174	Suppression of microRNA-29 expression by TGF- $\beta$ promotes collagen expression and renal fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2012</b> , 23, 252-65	12.7	385
173	Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. <i>Diabetes</i> , <b>2008</b> , 57, 2461-9	0.9	334
172	Low testosterone levels are common and associated with insulin resistance in men with diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 1834-40	5.6	291
171	miR-200a Prevents renal fibrogenesis through repression of TGF- $\beta$ expression. <i>Diabetes</i> , <b>2011</b> , 60, 280-7	0.9	279
170	Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. <i>Nature Reviews Nephrology</i> , <b>2016</b> , 12, 73-81	14.9	277
169	Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. <i>Diabetes</i> , <b>2004</b> , 53, 1813-23	0.9	258
168	The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. <i>Diabetes Care</i> , <b>2011</b> , 34, 861-6	14.6	246
167	Diabetic kidney disease. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15018	51.1	241
166	Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. <i>Diabetes</i> , <b>2004</b> , 53, 989-97	0.9	233
165	Unrecognized anemia in patients with diabetes: a cross-sectional survey. <i>Diabetes Care</i> , <b>2003</b> , 26, 1164-9	14.6	232
164	Dietary salt intake and mortality in patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2011</b> , 34, 703-9	14.6	228
163	Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2006</b> , 17, 2484-94	12.7	218
162	An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. <i>Kidney International</i> , <b>2011</b> , 80, 282-7	9.9	217
161	Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2005</b> , 16, 2363-72	12.7	180
160	Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. <i>Circulation Research</i> , <b>2010</b> , 107, 888-97	15.7	179
159	Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. <i>Journal of Hypertension</i> , <b>2012</b> , 30, 375-83	1.9	151

158	ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. <i>Diabetes</i> , <b>2008</b> , 57, 1018-25	0.9	147
157	Transforming growth factor- $\beta$ -mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. <i>Kidney International</i> , <b>2014</b> , 85, 352-61	9.9	137
156	Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment co-existing with NIDDM [NEFRON] 11). <i>Diabetes Care</i> , <b>2009</b> , 32, 1497-502	14.6	132
155	The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. <i>Diabetologia</i> , <b>2018</b> , 61, 2098-2107	10.3	125
154	Nutrient sensing, autophagy, and diabetic nephropathy. <i>Diabetes</i> , <b>2012</b> , 61, 23-9	0.9	125
153	Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. <i>Circulation Research</i> , <b>2012</b> , 110, 1067-76	15.7	121
152	Interactions between renin angiotensin system and advanced glycation in the kidney. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2005</b> , 16, 2976-84	12.7	118
151	Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?. <i>Gut</i> , <b>2020</b> , 69, 841-851	19.2	114
150	Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?. <i>Diabetes Care</i> , <b>2006</b> , 29, 1560-6	14.6	102
149	Dedifferentiation of immortalized human podocytes in response to transforming growth factor- $\beta$ a model for diabetic podocytopathy. <i>Diabetes</i> , <b>2011</b> , 60, 1779-88	0.9	97
148	PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. <i>Nephrology Dialysis Transplantation</i> , <b>2006</b> , 21, 2399-405	4.3	89
147	Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , <b>2010</b> , 298, F763-70	4.3	88
146	Increased thrombotic vascular events after change of statin. <i>Lancet, The</i> , <b>1998</b> , 352, 1830-1	4.0	88
145	Targeted reduction of advanced glycation improves renal function in obesity. <i>Kidney International</i> , <b>2011</b> , 80, 190-8	9.9	83
144	Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. <i>Diabetes</i> , <b>2010</b> , 59, 3208-15	0.9	83
143	Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2011</b> , 22, 537-44	12.7	83
142	Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2008</b> , 295, E323-30	6	83
141	Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse. <i>Diabetes</i> , <b>2010</b> , 59, 3198-207	0.9	81

140	The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). <i>Medical Journal of Australia</i> , <b>2006</b> , 185, 140-4	4	75
139	Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes. <i>Diabetes</i> , <b>2014</b> , 63, 3915-25	0.9	64
138	Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. <i>Journal of Hypertension</i> , <b>2010</b> , 28, 780-8	1.9	64
137	Post-translational modification of plant-made foreign proteins; glycosylation and beyond. <i>Biotechnology Advances</i> , <b>2012</b> , 30, 410-8	17.8	63
136	Anemia in diabetes: marker or mediator of microvascular disease?. <i>Nature Clinical Practice Nephrology</i> , <b>2007</b> , 3, 20-30		63
135	The epidemiology of hemoglobin levels in patients with type 2 diabetes. <i>American Journal of Kidney Diseases</i> , <b>2006</b> , 48, 537-45	7.4	59
134	Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. <i>Kidney International</i> , <b>2010</b> , 78, 287-95	9.9	58
133	Serum lipids and the progression of nephropathy in type 1 diabetes. <i>Diabetes Care</i> , <b>2006</b> , 29, 317-22	14.6	53
132	Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. <i>Diabetes</i> , <b>2012</b> , 61, 2105-13	0.9	50
131	Advanced glycation end products. <i>Contributions To Nephrology</i> , <b>2011</b> , 170, 66-74	1.6	50
130	The arterial depressor response to chronic low-dose angiotensin II infusion in female rats is estrogen dependent. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2012</b> , 302, R159-65	3.2	50
129	AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. <i>Hypertension</i> , <b>2015</b> , 65, 1073-81	8.5	49
128	The molecular mediators of type 2 epithelial to mesenchymal transition (EMT) and their role in renal pathophysiology. <i>Expert Reviews in Molecular Medicine</i> , <b>2010</b> , 12, e17	6.7	49
127	Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 1891-7	14.6	48
126	Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes. <i>Diabetes Care</i> , <b>2014</b> , 37, 2593-600	14.6	48
125	Resveratrol Inhibits Growth of Experimental Abdominal Aortic Aneurysm Associated With Upregulation of Angiotensin-Converting Enzyme 2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2017</b> , 37, 2195-2203	9.4	48
124	Low testosterone and anaemia in men with type 2 diabetes. <i>Clinical Endocrinology</i> , <b>2009</b> , 70, 547-53	3.4	47
123	High-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damage. <i>Nephrology Dialysis Transplantation</i> , <b>2012</b> , 27, 1793-800	4.3	47

122	Reduced tubular cation transport in diabetes: prevented by ACE inhibition. <i>Kidney International</i> , <b>2003</b> , 63, 2152-61	9.9	46
121	Osteoprotegerin promotes vascular fibrosis via a TGF- $\beta$ autocrine loop. <i>Atherosclerosis</i> , <b>2011</b> , 218, 61-8	3.1	45
120	High-salt diet reveals the hypertensive and renal effects of reduced nephron endowment. <i>American Journal of Physiology - Renal Physiology</i> , <b>2010</b> , 298, F1384-92	4.3	44
119	Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes. <i>Clinical Science</i> , <b>2008</b> , 114, 313-20	6.5	43
118	Renal effects of dapagliflozin in patients with type 2 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , <b>2014</b> , 5, 53-61	4.5	42
117	Type 2 Diabetes and Heart Failure: Challenges and Solutions. <i>Current Cardiology Reviews</i> , <b>2016</b> , 12, 249-55	5.4	42
116	The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. <i>Diabetes and Metabolism</i> , <b>2017</b> , 43 Suppl 1, 2S20-2S27	5.4	41
115	Activation of the Renin-Angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouse. <i>Hypertension</i> , <b>2012</b> , 60, 98-105	8.5	41
114	TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. <i>Clinical Science</i> , <b>2012</b> , 123, 547-55	6.5	41
113	Towards understanding the inherited susceptibility for nephropathy in diabetes. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2012</b> , 21, 195-202	3.5	41
112	Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. <i>Clinical Science</i> , <b>2012</b> , 123, 519-29	6.5	40
111	Angiotensin converting enzyme 2 and atherosclerosis. <i>Atherosclerosis</i> , <b>2013</b> , 226, 3-8	3.1	39
110	Investigating structural and biochemical correlates of ganglion cell dysfunction in streptozotocin-induced diabetic rats. <i>Experimental Eye Research</i> , <b>2009</b> , 88, 1076-83	3.7	39
109	Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 406-421	15.9	39
108	Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. <i>Atherosclerosis</i> , <b>2007</b> , 195, 17-22	3.1	37
107	Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. <i>Clinical Science</i> , <b>2006</b> , 110, 109-16	6.5	37
106	Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. <i>Molecular and Cellular Endocrinology</i> , <b>2014</b> , 394, 13-20	4.4	36
105	Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. <i>Nephrology Dialysis Transplantation</i> , <b>2006</b> , 21, 1611-7	4.3	36

104	Transient Intermittent Hyperglycemia Accelerates Atherosclerosis by Promoting Myelopoiesis. <i>Circulation Research</i> , <b>2020</b> , 127, 877-892	15.7	35
103	Deficiency in Apoptosis-Inducing Factor Recapitulates Chronic Kidney Disease via Aberrant Mitochondrial Homeostasis. <i>Diabetes</i> , <b>2016</b> , 65, 1085-98	0.9	34
102	Added value of soluble tumor necrosis factor- $\beta$ receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes. <i>Diabetes Care</i> , <b>2014</b> , 37, 2334-42	14.6	34
101	The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. <i>American Journal of Physiology - Renal Physiology</i> , <b>2010</b> , 299, F528-35	4.3	34
100	Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system. <i>Journal of Hypertension</i> , <b>2006</b> , 24, S57-63	1.9	34
99	Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 1827-33	14.6	33
98	The high prevalence of anemia in diabetes is linked to functional erythropoietin deficiency. <i>Seminars in Nephrology</i> , <b>2006</b> , 26, 275-82	4.8	33
97	ACE2 deficiency shifts energy metabolism towards glucose utilization. <i>Metabolism: Clinical and Experimental</i> , <b>2015</b> , 64, 406-15	12.7	32
96	Epigenetic Mechanisms in Diabetic Kidney Disease. <i>Current Diabetes Reports</i> , <b>2016</b> , 16, 31	5.6	28
95	Hyperfiltration in type 1 diabetes: does it exist and does it matter for nephropathy?. <i>Diabetologia</i> , <b>2012</b> , 55, 1505-13	10.3	28
94	Cardiovascular disease: what's all the AGE/RAGE about?. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , <b>2010</b> , 10, 7-15	1.1	28
93	Blood pressure lowering for the prevention and treatment of diabetic kidney disease. <i>Drugs</i> , <b>2006</b> , 66, 2213-34	12.1	28
92	Glycemic exposure, glycemic control, and metabolic karma in diabetic complications. <i>Advances in Chronic Kidney Disease</i> , <b>2014</b> , 21, 311-7	4.7	27
91	The role and management of sympathetic overactivity in cardiovascular and renal complications of diabetes. <i>Diabetes and Metabolism</i> , <b>2013</b> , 39, 290-8	5.4	26
90	Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosis. <i>Clinical Science</i> , <b>2014</b> , 127, 485-97	6.5	26
89	Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes. <i>American Journal of Physiology - Renal Physiology</i> , <b>2014</b> , 306, F773-80	4.3	25
88	Direct antiatherosclerotic effects of PPAR agonists. <i>Current Opinion in Lipidology</i> , <b>2009</b> , 20, 24-9	4.4	25
87	Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice. <i>Atherosclerosis</i> , <b>2014</b> , 235, 444-8	3.1	24

86	Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin-(1-7). <i>Clinical Science</i> , <b>2012</b> , 123, 29-37	6.5	24
85	The CARI guidelines. Prevention of progression of kidney disease. <i>Nephrology</i> , <b>2006</b> , 11 Suppl 1, S2-197	2.2	24
84	PPAR Agonists and Cardiovascular Disease in Diabetes. <i>PPAR Research</i> , <b>2008</b> , 2008, 245410	4.3	22
83	HDL composition predicts new-onset cardiovascular disease in patients with type 1 diabetes. <i>Diabetes Care</i> , <b>2007</b> , 30, 2706-7	14.6	22
82	Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. <i>Diabetes Therapy</i> , <b>2016</b> , 7, 439-54	3.6	22
81	Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2759-2767	6.7	21
80	Genetic deletion of cell division autoantigen 1 retards diabetes-associated renal injury. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2013</b> , 24, 1782-92	12.7	20
79	Pathogenesis and progression of proteinuria. <i>Contributions To Nephrology</i> , <b>2011</b> , 170, 48-56	1.6	20
78	Relationship Between Plasma 8-OH-Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	19
77	The intestinal vitamin D receptor in inflammatory bowel disease: inverse correlation with inflammation but no relationship with circulating vitamin D status. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284818822566	4.7	18
76	Glycated and carboxy-methylated proteins do not directly activate human vascular smooth muscle cells. <i>Kidney International</i> , <b>2005</b> , 68, 2756-65	9.9	18
75	Excess Mortality in Patients With Type 1 Diabetes Without Albuminuria-Separating the Contribution of Early and Late Risks. <i>Diabetes Care</i> , <b>2018</b> , 41, 748-754	14.6	17
74	Association of the SLC22A1, SLC22A2, and SLC22A3 genes encoding organic cation transporters with diabetic nephropathy and hypertension. <i>Annals of Medicine</i> , <b>2010</b> , 42, 296-304	1.5	17
73	High nephron endowment protects against salt-induced hypertension. <i>American Journal of Physiology - Renal Physiology</i> , <b>2012</b> , 303, F253-8	4.3	15
72	The management of diabetes in indigenous Australians from primary care. <i>BMC Public Health</i> , <b>2007</b> , 7, 303	4.1	14
71	Association of dietary sodium intake with atherogenesis in experimental diabetes and with cardiovascular disease in patients with Type 1 diabetes. <i>Clinical Science</i> , <b>2013</b> , 124, 617-26	6.5	13
70	New approaches to the treatment of nephropathy in diabetes. <i>Expert Opinion on Investigational Drugs</i> , <b>2011</b> , 20, 1057-71	5.9	13
69	A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations. <i>Contemporary Clinical Trials</i> , <b>2020</b> , 90, 105882	2.3	13



68	Diabetes: bardoxolone improves kidney function in type 2 diabetes. <i>Nature Reviews Nephrology</i> , <b>2011</b> , 7, 552-3	14.9	12
67	Screening for chronic kidney disease in patients with diabetes: are we missing the point?. <i>Nature Clinical Practice Nephrology</i> , <b>2008</b> , 4, 2-3		12
66	Phase 4 Studies in Heart Failure - What is Done and What is Needed?. <i>Current Cardiology Reviews</i> , <b>2016</b> , 12, 216-30	2.4	12
65	Coeliac disease, gluten-free diet and the development and progression of albuminuria in children with type 1 diabetes. <i>Pediatric Diabetes</i> , <b>2013</b> , 14, 455-8	3.6	11
64	Relationship between urinary sodium excretion over time and mortality in type 2 diabetes. <i>Diabetes Care</i> , <b>2014</b> , 37, e62-3	14.6	11
63	Into the light? Diabetic nephropathy and vitamin D. <i>Lancet, The</i> , <b>2010</b> , 376, 1521-2	4.0	11
62	Management of dyslipidaemia in patients with type 2 diabetes in Australian primary care. <i>Medical Journal of Australia</i> , <b>2007</b> , 186, 128-30	4	11
61	Association between intrarenal arterial resistance and diastolic dysfunction in type 2 diabetes. <i>Cardiovascular Diabetology</i> , <b>2008</b> , 7, 15	8.7	11
60	Northern Territory perspectives on heart failure with comorbidities – Understanding trial validity and exploring collaborative opportunities to broaden the evidence base. <i>Heart Lung and Circulation</i> , <b>2015</b> , 24, 536-43	1.8	10
59	Effects of Diabetes Medications Targeting the Incretin System on the Kidney. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2018</b> , 13, 321-323	6.9	10
58	Identification of obesity in patients with type 2 diabetes from Australian primary care: the NEFRON-5 study. <i>Diabetes Care</i> , <b>2006</b> , 29, 2723-5	14.6	10
57	RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor- $\beta$ and Increasing Resistance to Apoptosis. <i>Diabetes</i> , <b>2018</b> , 67, 960-973	0.9	9
56	Does a nephron deficit exacerbate the renal and cardiovascular effects of obesity?. <i>PLoS ONE</i> , <b>2013</b> , 8, e73095	3.7	9
55	The CARI guidelines. Prevention of progression of kidney disease: pre-dialysis education for patients with chronic kidney disease. <i>Nephrology</i> , <b>2007</b> , 12 Suppl 1, S46-8	2.2	9
54	Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes. <i>Diabetologia</i> , <b>2020</b> , 63, 1424-1434	10.3	8
53	Dicarbonyl-mediated AGEing and diabetic kidney disease. <i>Journal of Nephrology</i> , <b>2020</b> , 33, 909-915	4.8	7
52	Origin of the Y chromosome influences intrarenal vascular responsiveness to angiotensin I and angiotensin (1-7) in stroke-prone spontaneously hypertensive rats. <i>Hypertension</i> , <b>2014</b> , 64, 1376-83	8.5	7
51	Emerging drugs for managing kidney disease in patients with diabetes. <i>Expert Opinion on Emerging Drugs</i> , <b>2013</b> , 18, 55-70	3.7	7



50	A preliminary evaluation of bardoxolone methyl for the treatment of diabetic nephropathy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2012</b> , 8, 1015-22	5.5	7
49	The assessment of kidney function by general practitioners in Australian patients with type 2 diabetes (NEFRON-2). <i>Medical Journal of Australia</i> , <b>2006</b> , 185, 259-62	4	7
48	Contextualizing Genetics for Regional Heart Failure Care. <i>Current Cardiology Reviews</i> , <b>2016</b> , 12, 231-42	2.4	7
47	: Type 2 Diabetes and Readmission for Heart Failure. <i>Clinical Medicine Insights: Cardiology</i> , <b>2018</b> , 12, 117954681877958	3.5	7
46	The assessment and management of albuminuria in primary care. <i>Diabetes Research and Clinical Practice</i> , <b>2008</b> , 80, 83-8	7.4	6
45	The CARI guidelines. Prevention of progression of kidney disease: early detection of patients with kidney disease. <i>Nephrology</i> , <b>2007</b> , 12 Suppl 1, S37-40	2.2	6
44	The CARI guidelines. Prevention of progression of kidney disease: early referral of patients with pre-end-stage kidney disease. <i>Nephrology</i> , <b>2007</b> , 12 Suppl 1, S41-3	2.2	6
43	Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan. <i>Trials</i> , <b>2020</b> , 21, 459	2.8	5
42	Losing Control: Positive and Negative Feedback in the Renin Angiotensin System. <i>Current Hypertension Reviews</i> , <b>2009</b> , 5, 222-226	2.3	5
41	Diabetes: Assessing renal risk in patients with type 2 diabetes. <i>Nature Reviews Nephrology</i> , <b>2013</b> , 9, 559-60.9	4.9	4
40	The CARI guidelines. Prevention of progression of kidney disease: weight reduction in obese patients with chronic kidney disease. <i>Nephrology</i> , <b>2007</b> , 12 Suppl 1, S49-51	2.2	4
39	The Long-Term Incidence of Hospitalization for Ketoacidosis in Adults with Established T1D-A Prospective Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	4
38	A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure. <i>Clinical Medicine Insights: Cardiology</i> , <b>2016</b> , 10, 163-171	3.2	3
37	Non-invasive Risk Stratification for Coronary Artery Disease: Is It Time for Subclassifications?. <i>Current Cardiology Reports</i> , <b>2019</b> , 21, 87	4.2	3
36	Longitudinal analysis of low-molecular weight fluorophores in type 1 diabetes mellitus. <i>Journal of Medical Investigation</i> , <b>2008</b> , 55, 29-36	1.2	3
35	Severe acute respiratory syndrome coronavirus 2 as a potential cause of type 1 diabetes facilitated by spike protein receptor binding domain attachment to human islet cells: An illustrative case study and experimental data. <i>Diabetic Medicine</i> , <b>2021</b> , 38, e14608	3.5	3
34	Bardoxolone: augmenting the Yin in chronic kidney disease. <i>Diabetes and Vascular Disease Research</i> , <b>2011</b> , 8, 303-4	3.3	2
33	Can you reduce your AGE?: Strategies to prevent AGE accumulation in diabetes. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2007</b> , 4, 85-92		2

32	The CARI guidelines. Prevention of progression of kidney disease: autosomal-dominant polycystic kidney disease. <i>Nephrology</i> , <b>2007</b> , 12 Suppl 1, S52-6	2.2	2
31	Specific management of IgA nephropathy: role of cyclosporin and other therapies. <i>Nephrology</i> , <b>2006</b> , 11, S149-S153	2.2	2
30	Forensic interrogation of diabetic endothelitis in cardiovascular diseases and clinical translation in heart failure. <i>World Journal of Cardiology</i> , <b>2020</b> , 12, 409-418	2.1	2
29	Dietary intake and hospitalisation due to diabetic ketoacidosis and hypoglycaemia in individuals with type 1 diabetes. <i>Scientific Reports</i> , <b>2021</b> , 11, 1638	4.9	2
28	Specific management of IgA nephropathy: role of triple therapy and cytotoxic therapy. <i>Nephrology</i> , <b>2006</b> , 11, S141-S145	2.2	1
27	Specific management of IgA nephropathy: role of tonsillectomy. <i>Nephrology</i> , <b>2006</b> , 11, S146-S148	2.2	1
26	Targeting the Pathobiology of Diabetic Kidney Disease.. <i>Advances in Chronic Kidney Disease</i> , <b>2021</b> , 28, 282-289	4.7	1
25	Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines. <i>Current Cardiology Reviews</i> , <b>2016</b> , 12, 166-79	2.4	1
24	Circulating Soluble ACE2 Plays an Independent Role to Protect against Vascular Damage in Diabetic Mice. <i>Antioxidants</i> , <b>2022</b> , 11, 987	7.1	1
23	Focal segmental glomerulosclerosis: correction of secondary causes. <i>Nephrology</i> , <b>2006</b> , 11, S194-S195	2.2	0
22	Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice. <i>Current Cardiology Reviews</i> , <b>2021</b> , 17, e160721187934	2.4	0
21	Perspectives On Optimizing Chronic Heart Failure Care Beyond Randomised Controlled Trials - What do we Consolidate and how do we Plan for the Future?. <i>Current Cardiology Reviews</i> , <b>2019</b> , 15, 158-160	2.4	0
20	Diabetic kidney disease: new treatment options. <i>Diabetes Management</i> , <b>2013</b> , 3, 123-130	0	
19	Preventing Progression of Chronic Kidney Disease: Renin-Angiotensin-Aldosterone System Blockade Beyond Blood Pressure <b>2014</b> , 123-134		
18	The CARI guidelines. Prevention of progression of kidney disease: regular and frequent follow-up of patients with pre-end-stage kidney disease. <i>Nephrology</i> , <b>2007</b> , 12 Suppl 1, S44-5	2.2	
17	Analgesic-associated kidney disease. <i>Nephrology</i> , <b>2006</b> , 11, S123-S125	2.2	
16	Renal artery stenosis. <i>Nephrology</i> , <b>2006</b> , 11, S126-S131	2.2	
15	Specific management of IgA nephropathy: role of steroid therapy. <i>Nephrology</i> , <b>2006</b> , 11, S132-S136	2.2	

14	Specific management of IgA nephropathy: role of fish oil. <i>Nephrology</i> , <b>2006</b> , 11, S137-S140	2.2
13	Membranous nephropathy: role of alkylating agents. <i>Nephrology</i> , <b>2006</b> , 11, S154-S161	2.2
12	Membranous nephropathy: role of steroids. <i>Nephrology</i> , <b>2006</b> , 11, S162-S165	2.2
11	Membranous nephropathy: role of cyclosporin therapy. <i>Nephrology</i> , <b>2006</b> , 11, S166-S169	2.2
10	Treatment of secondary membranous nephropathy. <i>Nephrology</i> , <b>2006</b> , 11, S170-S171	2.2
9	Idiopathic membranous nephropathy: use of other therapies. <i>Nephrology</i> , <b>2006</b> , 11, S172-S174	2.2
8	Reflux nephropathy. <i>Nephrology</i> , <b>2006</b> , 11, S175-S181	2.2
7	Focal segmental glomerulosclerosis: treatment with steroids. <i>Nephrology</i> , <b>2006</b> , 11, S182-S184	2.2
6	Focal segmental glomerulosclerosis: use of cyclosporin A. <i>Nephrology</i> , <b>2006</b> , 11, S185-S188	2.2
5	Focal segmental glomerulosclerosis: cytotoxic therapy. <i>Nephrology</i> , <b>2006</b> , 11, S189-S193	2.2
4	Focal segmental glomerulosclerosis: use of other therapies. <i>Nephrology</i> , <b>2006</b> , 11, S196-S197	2.2
3	Anemia and Diabetic Nephropathy <b>2006</b> , 527-548	
2	Preventing Progression of Chronic Kidney Disease: Diet and Lifestyle <b>2014</b> , 113-122	
1	Dimeric phosphorylation of glyoxalase I alters its symmetry and substrate binding mechanism: simulation studies. <i>Journal of Biomolecular Structure and Dynamics</i> , <b>2021</b> , 1-15	3.6